Eli Lilly $LLY said its experimental drug retatrutide helped patients with Type 2 diabetes shed up to 16.8% of their body weight over 40 weeks in a Phase 3 trial, outpacing all diabetes drugs now available.
Eli Lilly's experimental drug retatrutide helped Type 2 diabetes patients lose up to 16.8% of their body weight in a Phase 3 trial, topping all rivals
NurPhoto / Getty Images
Eli Lilly $LLY said its experimental drug retatrutide helped patients with Type 2 diabetes shed up to 16.8% of their body weight over 40 weeks in a Phase 3 trial, outpacing all diabetes drugs now available.
The company announced results from TRANSCEND-T2D-1, a Phase 3 trial evaluating retatrutide as an adjunct to diet and exercise in 537 adults with Type 2 diabetes and inadequate blood sugar control. Patients had a mean diabetes duration of 2.5 years.
The drug reached its main goal by lowering A1C, which measures long-term blood sugar control, by up to 2.0% over 40 weeks. By comparison, the placebo group saw a 0.8% drop. For a key secondary endpoint, patients on the highest 12 mg dose lost an average of 36.6 pounds, or 16.8% of their body weight, in an analysis limited to those who completed treatment. Including patients who discontinued, weight loss at the highest dose averaged 15.3%. Weight loss continued through the end of the treatment period, with no plateau observed, Lilly said.
"For many people with type 2 diabetes, it is a struggle to achieve both A1C control and weight loss, since obesity has historically been harder to treat for those with type 2 diabetes," Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a statement.
Unlike Mounjaro and Novo Nordisk's Ozempic, which act on one or two hormonal pathways, retatrutide is designed to activate receptors for three gut hormones: GLP-1, GIP and glucagon. The drug is taken once weekly.
At the 12 mg dose, nausea was reported by 26.5% of patients, diarrhea by 22.8%, and vomiting by 17.6%, Lilly said. Roughly 5% of patients on the 12 mg dose left the study because of side effects. Dysesthesia — an unpleasant nerve sensation — was reported at low rates across all doses; the majority of those cases resolved before the trial concluded, Lilly said.
The drug also showed improvements in cardiovascular risk factors including non-HDL cholesterol, triglycerides and systolic blood pressure, Lilly said.
Eli Lilly stock was largely flat in Thursday morning trading, while Novo Nordisk stock fell 2.3%.
More detailed results will be presented at the American Diabetes Association's Scientific Sessions in June. The company has seven more Phase 3 retatrutide trials with results due before the end of 2026, according to CNBC. Retatrutide is not approved for any indication and remains legally available only to clinical trial participants.
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.